Special Issue "New Developments in the Treatment of Early-Stage and Advanced Melanoma"
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 3610
Interests: (uveal) melanoma; thyroid and other endocrine cancers; colorectal cancer
Special Issues, Collections and Topics in MDPI journals
This Special Issue is the second edition of the previous one, "Advanced Melanoma", (https://www.mdpi.com/journal/cancers/special_issues/Advanced_Melanoma).
In recent years, new systemic treatment options have become available for patients with advanced melanoma. These treatments are also given in the (neo)adjuvant setting of earlier stages of melanoma.
BRAF/MEK inhibitors, which act through the strong inhibition of the mutated BRAF protein, have been used in targeted therapy as about half of the patients with melanoma have this mutation. This therapy is initially very effective, but the tumor usually acquires resistance to these drugs within a year after the start of treatment. It is also currently used in the adjuvant setting in stage III melanoma.
Moreover, patients can be treated with immunotherapy using checkpoint inhibitors, regardless of their mutation status. The systemic treatment with checkpoint inhibitors consists of antibodies that stimulate T lymphocyte activation by blocking co-inhibitory signals. Treatment with these therapies can lead to long-term responses lasting several years. Checkpoint inhibitors are also used as adjuvant treatment in stage II and III melanoma and in the neo-adjuvant setting in stage III melanoma. However, the disease remains progressive in approximately half of the advanced patients under treatment using these forms of therapy. Hence, new therapies and clinical trials are still needed.
However, most efficacy data have been collected from randomized phase III trials with strict inclusion and exclusion criteria. Thus, there is a need for real-life data from registries in which, e.g., older patients and patients with comorbidities are also included. In addition, questions remain on how to evaluate and follow up patients while on treatment and also thereafter.
This Special Issue of Cancers will present the latest research on the abovementioned topics in early stage and advanced melanoma.
Dr. Ellen Kapiteijn
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- early stage and advanced melanoma
- prognostic factors
- clinical trials
- real-life data
- radiological evaluation and follow up
- targeted therapy immunotherapy
- new developments